ESR1 and breast carcinoma: Approximately 70% of breast cancer patients—positive for estrogen receptor (ER) and progesterone receptor (PR)—receive hormone therapy, such as blocking ER to inhibit estrogen signaling, as the first-line treatment for patients with luminal breast cancer [4, 5].